February 25, 2021

Moderna Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Updates

February 24, 2021

Moderna Announces Additional Capital Investments to Increase Global Manufacturing Capacity for COVID-19 Vaccine

February 24, 2021

Moderna Announces it has Shipped Variant-Specific Vaccine Candidate, mRNA-1273.351, to NIH for Clinical Study

February 18, 2021

Moderna to Present at Upcoming Investor Conferences in February and March 2021

February 17, 2021

European Commission Purchases Additional 150 Million Doses of COVID-19 Vaccine Moderna

February 16, 2021

Moderna Provides U.S. COVID-19 Vaccine Supply Update

February 12, 2021

Canada Purchases Additional 4 Million Doses of Moderna’s COVID-19 Vaccine

February 11, 2021

U.S. Government Purchases Additional 100 Million Doses of Moderna’s COVID-19 Vaccine

February 11, 2021

Qatar Ministry of Public Health Issues Emergency Use Authorization for COVID-19 Vaccine Moderna

February 9, 2021

Moderna Announces COVID-19 Vaccine Supply Agreements with the Government of Taiwan for 5 Million Doses and the Government of Colombia for 10 Million Doses

February 4, 2021

Moderna to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, February 25, 2021

February 3, 2021

Singapore Health Sciences Authority (HSA) Approves Interim Authorization of COVID-19 Vaccine Moderna For Use

February 3, 2021

Moderna Announces Amendment to Supply Agreement with Switzerland for an Additional 6 Million Doses of COVID-19 Vaccine Moderna

January 27, 2021

Moderna Confirms Discussions with U.S. Government for Additional 100 Million Doses of the Moderna COVID-19 Vaccine

January 26, 2021

Moderna Provides U.S. COVID-19 Vaccine Supply Update

January 25, 2021

Moderna to Host Conference Call on COVID-19 Variants Announcement on Monday, Jan. 25

January 25, 2021

Moderna COVID-19 Vaccine Retains Neutralizing Activity Against Emerging Variants First Identified in the U.K. and the Republic of South Africa

January 21, 2021

Moderna Announces First Participant Dosed in Phase 1/2 Study of Moderna COVID-19 Vaccine in Japan Led by Takeda

January 12, 2021

José M. Vega, M.D. Joins Moderna as Chief Safety Officer

January 12, 2021

Swissmedic Authorizes COVID-19 Vaccine Moderna for Use in Switzerland

January 11, 2021

Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

January 8, 2021

United Kingdom Medicines and Healthcare products Regulatory Agency Authorizes Use of COVID-19 Vaccine Moderna

January 7, 2021

Corinne Le Goff, Pharm.D. Will Join Moderna as Chief Commercial Officer on January 19

January 6, 2021

European Commission Authorizes COVID-19 Vaccine Moderna in Europe

January 4, 2021

Israeli Ministry of Health Authorizes COVID-19 Vaccine Moderna for Use in Israel

January 4, 2021

Moderna Provides COVID-19 Vaccine Supply Update

January 4, 2021

Moderna to Provide Business and Pipeline Updates at the 2021 J.P. Morgan Healthcare Conference

December 31, 2020

Moderna Announces Publication of Results from the Pivotal Phase 3 Trial of the Moderna COVID-19 Vaccine in The New England Journal of Medicine

December 31, 2020

Moderna Confirms 40 Million COVID-19 Vaccine Dose Supply Agreement with the Government of the Republic of Korea

December 30, 2020

Recipharm and Moderna Finalize Agreement for Aseptic Drug Product Manufacturing and Fill-Finish for Supply to Countries Outside the U.S.

December 29, 2020

Moderna Confirms Discussions With the Government of South Korea to Supply South Korea With 40 Million Doses of COVID-19 Vaccine

December 29, 2020

Moderna to Present at the Goldman Sachs 13th Annual Healthcare CEOs Unscripted Conference: A View from the Top

December 23, 2020

Health Canada Authorizes Moderna COVID-19 Vaccine in Canada

December 19, 2020

U.S. CDC Advisory Committee on Immunization Practices Recommends Vaccination with Moderna’s COVID-19 Vaccine for Persons 18 Years and Older

December 18, 2020

Moderna Announces FDA Authorization of Moderna COVID-19 Vaccine in U.S.

December 18, 2020

European Commission Exercises Option for Additional 80 Million Doses of Moderna’s COVID-19 Vaccine Candidate

December 17, 2020

Moderna Receives FDA Advisory Committee Vote Supporting Emergency Use for Moderna’s Vaccine Against COVID-19 in the United States

December 14, 2020

Moderna Confirms Supply Agreement with the Ministry of Health to Supply Singapore with mRNA Vaccine Against COVID-19 (mRNA-1273)

December 11, 2020

U.S. Government Exercises 1st Option for Additional 100 Million Doses of Moderna’s COVID-19 Vaccine Candidate

December 10, 2020

Moderna Announces First Participants Dosed in Phase 2/3 Study of COVID-19 Vaccine Candidate in Adolescents

December 8, 2020

Switzerland Exercises Increased Option for 7.5 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

December 7, 2020

Canada Exercises Increased Option for Total of 40 Million Doses of mRNA Vaccine Candidate Against COVID-19 (mRNA-1273)

December 4, 2020

Moderna Announces Amendment to Supply Agreement with the Ministry of Health of Israel to Supply Additional Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

December 3, 2020

Moderna Provides Updates on the Clinical Development and Production of Its COVID-19 Vaccine Candidate

November 30, 2020

Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization

November 29, 2020

Moderna Announces Amendment to Current Supply Agreement with United Kingdom Government for an Additional 2 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

November 27, 2020

Moderna to Present at Upcoming Investor Conferences in December 2020

November 25, 2020

Moderna Announces the European Commission’s Approval of Advance Purchase Agreement for Initial 80 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

November 17, 2020

European Medicines Agency Begins Rolling Review of Moderna’s mRNA Vaccine Candidate Against COVID-19 (mRNA-1273)

November 17, 2020

Moderna Announces Supply Agreement with United Kingdom Government to Supply mRNA Vaccine Against COVID-19 (mRNA-1273) if Approved for Use

November 16, 2020

Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study

November 16, 2020

Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures

November 13, 2020

Swissmedic Begins Rolling Review of Moderna’s mRNA Vaccine Against COVID-19 (mRNA-1273)

November 11, 2020

Moderna Has Completed Case Accrual for First Planned Interim Analysis of its mRNA Vaccine Against COVID-19 (mRNA-1273)

November 11, 2020

Moderna Announces Clinical Updates on Personalized Cancer Vaccine Program

November 2, 2020

Moderna to Present at Upcoming Investor Conferences in November 2020

October 30, 2020

Moderna Named Top Employer by Science for Sixth Consecutive Year

October 29, 2020

Moderna Reports Third Quarter 2020 Financial Results and Provides Business Updates

October 29, 2020

Moderna Partners with Takeda and the Government of Japan to Supply 50 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273) to Japan

October 27, 2020

UK Medicines and Healthcare products Regulatory Agency Begins Rolling Review of Moderna’s mRNA Vaccine Against COVID-19 (mRNA-1273)

October 26, 2020

Moderna Announces Supply Agreement with the Ministry of Public Health to Supply Qatar with mRNA Vaccine Against COVID-19 (mRNA-1273)

October 22, 2020

Moderna Completes Enrollment of Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273)

October 15, 2020

Moderna to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020

October 14, 2020

Moderna Receives Confirmation of Eligibility for Submission of Marketing Authorization Application to the European Medicines Agency for mRNA Vaccine Against COVID-19 (mRNA-1273)

October 13, 2020

Moderna Announces Initiation of Rolling Submission to Health Canada for mRNA Vaccine Against COVID-19 (mRNA-1273)

October 8, 2020

DARPA Awards Moderna up to $56 Million to Enable Small-Scale, Rapid Mobile Manufacturing of Nucleic Acid Vaccines and Therapeutics

October 8, 2020

Moderna Announces Updates on Respiratory Syncytial Virus (RSV) Vaccine Program

September 29, 2020

Moderna Announces Publication in The New England Journal of Medicine of Interim Results From Older Adult Age Cohorts in Phase 1 Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)

September 28, 2020

Moderna to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference

September 22, 2020

Canada Exercises Increased Option for 20 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

September 17, 2020

Moderna Announces Progress Across Broad Portfolio and all Three Clinical Stage Therapeutic Areas at 2020 R&D Day

September 16, 2020

Moderna and Vertex Establish New Collaboration to Treat Cystic Fibrosis Using Gene Editing

September 16, 2020

Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH)

September 16, 2020

Moderna Announces First Commercial Organization Outside North America in Switzerland

September 10, 2020

Moderna Names Michael Mullette as Managing Director of New Canadian Subsidiary

September 9, 2020

Moderna to Present at Upcoming Investor Conferences in September 2020

September 8, 2020

Biopharma Leaders Unite to Stand with Science

September 3, 2020

Moderna to Host Virtual R&D Day on September 17, 2020

August 28, 2020

Moderna Confirms Discussions with the Ministry of Health, Labour and Welfare to Supply Japan with 40 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

August 26, 2020

Moderna to Present New Interim Clinical Data About mRNA Vaccine Against COVID-19 (mRNA-1273) at Advisory Committee on Immunization Practices (ACIP) Meeting

August 24, 2020

Moderna Confirms Advanced Discussions with European Commission to Supply Europe with 80 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

August 11, 2020

Moderna Announces Supply Agreement with U.S. Government for Initial 100 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

August 10, 2020

John Lepore Joins Moderna as Senior Vice President, Government Engagement

August 5, 2020

Moderna Reports Second Quarter 2020 Financial Results and Provides Business Updates

July 30, 2020

Moderna Announces Resignation of Dr. Elizabeth Nabel From Board of Directors

July 28, 2020

Moderna Announces Publication in The New England Journal of Medicine of Non-Human Primate Preclinical Viral Challenge Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)

July 27, 2020

Moderna Announces Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273) Begins

July 26, 2020

Moderna Announces Expansion of BARDA Agreement to Support Larger Phase 3 Program for Vaccine (mRNA-1273) Against COVID-19

July 24, 2020

Statement from Moderna on Patent Trial and Appeal Board (PTAB) Ruling

July 22, 2020

Moderna to Report Second Quarter 2020 Financial Results on Wednesday, August 5, 2020

July 14, 2020

Moderna Announces Publication in The New England Journal of Medicine of Interim Results From Phase 1 Study of Its mRNA Vaccine Against COVID-19 (mRNA-1273)

July 14, 2020

Moderna to Join the NASDAQ-100 Index Beginning July 20, 2020

July 9, 2020

Moderna and ROVI Announce Collaboration for OUS Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate

July 8, 2020

Moderna Completes Enrollment of Phase 2 Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)

July 1, 2020

Elizabeth Tallett Joins Moderna’s Board of Directors

June 25, 2020

Moderna and Catalent Announce Collaboration for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate

June 16, 2020

Moderna to Present at BMO 2020 Prescriptions for Success Healthcare Conference

June 15, 2020

Ray Jordan Joins Moderna as Chief Corporate Affairs Officer

June 11, 2020

Moderna Advances Late-Stage Development of its Vaccine (mRNA-1273) Against COVID-19

June 4, 2020

David Meline Joins Moderna as Chief Financial Officer

June 2, 2020

Moderna Highlights Advances in Platform Science and Innovative Vaccine Research at Third Annual Science Day

May 29, 2020

Moderna Announces First Participants in Each Age Cohort Dosed in Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

May 27, 2020

Moderna to Present at Upcoming Investor Conferences

May 26, 2020

Moderna to Host Virtual Science Day on June 2, 2020

May 18, 2020

Moderna Announces Pricing of Public Offering of Shares of Common Stock

May 18, 2020

Moderna Announces Proposed Public Offering of Shares of Common Stock

May 18, 2020

Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

May 15, 2020

Moderna Congratulates Dr. Moncef Slaoui on His Appointment to Oversee the White House’s Operation Warp Speed Initiative

May 12, 2020

Moderna Receives FDA Fast Track Designation for mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

May 8, 2020

Moderna to Present at Upcoming Investor Conferences

May 7, 2020

Moderna Reports First Quarter 2020 Financial Results and Provides Business Updates

May 1, 2020

Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna’s Vaccine (mRNA-1273) Against Novel Coronavirus

April 27, 2020

Moderna Announces IND Submitted to U.S. FDA for Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

April 23, 2020

Moderna to Report First Quarter 2020 Financial Results on Thursday, May 7th, 2020

April 16, 2020

Moderna Announces Award from U.S. Government Agency BARDA for up to $483 Million to Accelerate Development of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

April 14, 2020

Moderna Highlights Opportunity of mRNA Vaccines at its First Vaccines Day

April 10, 2020

Moderna Announces that Its 2020 Annual Meeting of Stockholders Will be Held in Virtual Format

April 8, 2020

Moderna to Present at 19th Annual Needham Healthcare Conference

April 7, 2020

Moderna to Host Virtual Vaccines Day on April 14, 2020

March 29, 2020

Moderna Provides Update on the Impact of COVID-19 on Business Operations and Clinical Program Development

March 25, 2020

Moderna to Present at MIT Lecture Series

March 16, 2020

Moderna Announces First Participant Dosed in NIH-led Phase 1 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

March 3, 2020

Moderna Completes Enrollment of Cytomegalovirus (CMV) Vaccine (mRNA-1647) Phase 2 Study

March 2, 2020

Moderna Announces Updated Plans for its March 4 Manufacturing & Digital Day Event

February 26, 2020

Moderna to Host Manufacturing & Digital Day on March 4, 2020

February 26, 2020

Moderna Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights Advancements in Core Modalities

February 24, 2020

Moderna Ships mRNA Vaccine Against Novel Coronavirus (mRNA-1273) for Phase 1 Study

February 24, 2020

Moderna to Present at Upcoming Investor Conferences

February 12, 2020

Moderna to Report Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26th, 2020

February 11, 2020

Moderna Announces Pricing of Public Offering of Shares of Common Stock

February 10, 2020

Moderna Announces Progress in Prophylactic Vaccines Modality with CMV Vaccine Phase 2 Study Data Now Expected in Third Quarter 2020 and Expands Investment in This Core Modality with Three New Development Candidates

February 10, 2020

Moderna Announces First Patient Enrolled in Phase 1/2 Study of mRNA-3704 for Methylmalonic Acidemia

February 10, 2020

Moderna Announces Proposed Public Offering of Shares of Common Stock

February 3, 2020

Sandra Horning, M.D. To Join Moderna’s Board of Directors

January 30, 2020

Melanie Ivarsson, Ph.D. Joins Moderna as Chief Development Officer

January 23, 2020

Moderna Announces Funding Award from CEPI to Accelerate Development of Messenger RNA (mRNA) Vaccine Against Novel Coronavirus

January 12, 2020

Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area

January 9, 2020

Moderna Announces Additional Positive Phase 1 Data from Cytomegalovirus (CMV) Vaccine (mRNA-1647) and First Participant Dosed in Phase 2 Study

January 6, 2020

Moderna to Provide Business and Pipeline Updates at the 2020 J.P. Morgan Healthcare Conference

December 11, 2019

Moderna Announces Key 2020 Investor and Analyst Events

December 10, 2019

François Nader, M.D., Joins Moderna’s Board of Directors

November 26, 2019

Moderna to Present at 31st Annual Piper Jaffray Healthcare Conference

November 6, 2019

Moderna Provides Business Updates and Reports Third Quarter 2019 Financial Results

November 5, 2019

Moderna to Present at Credit Suisse 28th Annual Healthcare Conference

October 24, 2019

Moderna Named Top Employer by Science for Fifth Consecutive Year

October 22, 2019

Moderna Receives FDA Fast Track Designation for Propionic Acidemia Program (mRNA-3927)

October 22, 2019

Moderna to Report Third Quarter 2019 Financial Results on Wednesday, November 6th, 2019

October 2, 2019

Moderna to Present Data From Two of Its Prophylactic mRNA Vaccines at IDWeek 2019

September 30, 2019

Moderna Announces Open IND for Propionic Acidemia Program (mRNA-3927)

September 26, 2019

Moderna Announces mRNA Immunotherapy Research Collaboration with Harvard University

September 25, 2019

Moderna to Present at Upcoming Investor Conferences

September 12, 2019

Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944)

September 12, 2019

Moderna Announces Positive Interim Results from Phase 1 Cytomegalovirus (CMV) Vaccine (mRNA-1647) Study and Progress Toward Phase 2 and Pivotal Trials

September 4, 2019

Moderna Appoints Tracey Franklin as Chief Human Resources Officer

August 29, 2019

Moderna to Host R&D Day on September 12, 2019

August 27, 2019

Moderna to Present at Upcoming Investor Conferences

August 19, 2019

Moderna Receives FDA Fast Track Designation for Zika Vaccine mRNA-1893

August 7, 2019

Moderna Provides Business Updates and Reports Second Quarter 2019 Financial Results

July 24, 2019

Moderna to Report Second Quarter 2019 Financial Results on Wednesday, August 7th, 2019

July 10, 2019

Moderna to Present at ROTH RNA Revolution Conference

June 18, 2019

Moderna to Present at BMO 2019 Prescriptions for Success Healthcare Conference

June 7, 2019

Moderna to Present at Goldman Sachs 40th Annual Global Healthcare Conference

June 1, 2019

Moderna Announces Presentation of Interim Data from Phase 1 Study of mRNA Personalized Cancer Vaccine at 2019 ASCO Annual Meeting

May 17, 2019

Moderna Announces Publication of Preclinical Data for Chikungunya Antibody Program

May 10, 2019

Moderna Announces Publication of Phase 1 Data for mRNA Vaccines Against Two Potential Pandemic Influenza Strains

May 8, 2019

Moderna Reports First Quarter 2019 Financial Results and Provides Business Updates

May 6, 2019

Moderna to Present at Bank of America Merrill Lynch 2019 Health Care Conference

April 29, 2019

Moderna to Present Preclinical Data at 2019 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

April 16, 2019

Moderna to Host Science Day on May 7, 2019 and Report First Quarter Financial Results on May 8, 2019

April 3, 2019

Moderna to Present at 18th Annual Needham Healthcare Conference

March 6, 2019

Moderna Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights Recent Pipeline Progress

March 4, 2019

Moderna to Present at Upcoming Investor Conferences in March

February 21, 2019

Moderna to Report Fourth Quarter and Full Year 2018 Financial Results on Wednesday, March 6, 2019

February 20, 2019

Phase 1 Data Published in Nature Communications Show Potential of mRNA Encoding VEGF-A as a Regenerative Therapeutic

February 12, 2019

Moderna Announces Positive Interim Phase 1 Data for First Combination Vaccine Against the Respiratory Viruses hMPV and PIV3

February 5, 2019

Moderna Announces Dosing of the First Monoclonal Antibody Encoded by mRNA in a Clinical Trial

January 30, 2019

Newly Published Pre-Clinical Data Show Intratumoral Injections of Messenger RNA Encoding Three Immune Modulators Stimulate Durable Anti-Cancer Responses in Treated and Distal Tumors

January 18, 2019

Dr. John Mendlein to Transition to an Advisory Role at Moderna and Join Flagship Pioneering as an Executive Partner

January 8, 2019

Moderna Announces Recent Progress in Its Immuno-Oncology and Rare Disease Programs and Highlights Corporate Objectives

January 2, 2019

Moderna to Provide Business and Pipeline Updates at the 2019 J.P. Morgan Healthcare Conference